The Impact of Non-Dysentery Shigella Infection on the Growth and Health of Children over Time (INSIGHT)—A Prospective Case–Control Study Protocol
-
Published:2024-08-15
Issue:8
Volume:12
Page:1677
-
ISSN:2076-2607
-
Container-title:Microorganisms
-
language:en
-
Short-container-title:Microorganisms
Author:
Chakraborty Subhra1ORCID, Dash Sampa2ORCID, Antara Nowrin Akbar2, Roy Bharati Rani2, Mamun Shamim Al2, Ali Mohammad2, Naz Farina2, Johura Fatema-Tuz1, Lewis Jade1ORCID, Afroze Farzana2ORCID, Hasan ABM Ali3, Sack David A.1ORCID, Ram Malathi1, Tofail Fahmida2ORCID, Ahmed Tahmeed2, Faruque A. S. G.2ORCID
Affiliation:
1. Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA 2. icddr,b, Dhaka 1212, Bangladesh 3. Kumudini Women’s Medical College Hospital, Mirzapur, Tangail 1940, Bangladesh
Abstract
(1) Shigella spp. (Shigella) is known for causing dysentery with blood in stool, but most children infected with Shigella have non-dysentery Shigella-associated diarrhea (NDSD). The World Health Organization recommends the use of antibiotics when diarrhea is bloody, leaving most NDSD cases untreated. The absence of dysentery may not indicate a low risk of death and severe morbidity. Rapid diagnosis and treatment of shigellosis in vulnerable, young children may be lifesaving. INSIGHT aims to determine the potential benefit of identifying NDSD cases (n = 296) and their outcomes compared to cases of Shigella dysentery [DS (n = 148)] and non-Shigella watery diarrhea [WD (n = 148)]. (2) Children seeking care at hospitals in Bangladesh will be enrolled and followed for 1 year (NDSD and DS) or 90 days (WD). We will determine the impact of NDSD on morbidity, mortality, gut health, nutritional status, and cognitive development compared to DS and WD in children and whether the simple “Rapid LAMP-based Diagnostic Test (RLDT)” can accelerate the detection and treatment of shigellosis in the clinical settings of rural Bangladesh. (3) INSIGHT will determine the impact of NDSD in children and determine if the treatment guidelines of shigellosis need to be revisited to improve clinical outcomes and the development of these children.
Funder
National Institute of Allergy and Infectious Diseases of the National Institute of Health
Reference35 articles.
1. Morbidity and mortality due to shigella and enter-otoxigenic Escherichia coli diarrhoea: The Global Burden of Disease Study 1990–2016;Khalil;Lancet Infect Dis.,2018 2. Burden of enterotoxigenic Escherichia coli and Shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: A modelling analysis;Anderson;Lancet Glob. Health,2019 3. GBD 2013 DALYs and HALE Collaborators, Murray, C.J., Barber, R.M., Foreman, K.J., Abbasoglu, O.A., Abd-Allah, F., Abera, S.F., Aboyans, V., Abraham, J.P., and Abubakar, I. (2015). Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: Quantifying the epidemiological transition. Lancet, 386, 2287–2323. 4. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010;Murray;Lancet,2012 5. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study;Kotloff;Lancet,2013
|
|